# Exenatide (Byetta / Bydureon)

> First-in-class GLP-1 receptor agonist for type 2 diabetes.

Source: https://peptides.cafe/peptide/exenatide
Category: GLP-1 Agonist · Metabolic
Tag: FDA-Approved · Metabolic

## Mechanism
Synthetic version of exendin-4 (originally from Gila monster saliva). Activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and increase satiety.

## Research areas
- Type 2 diabetes
- Weight management (off-label)

## Common research protocols
- Byetta: 5–10 mcg SC twice daily.
- Bydureon (extended release): 2 mg SC once weekly.

## Study summaries
- "EXSCEL trial" — NEJM (2017): Cardiovascular safety established for once-weekly exenatide.

## Considerations
- FDA-approved.
- Nausea common; pancreatitis warning.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.